Sentinel lymph node dissection and the current status of American trials on breast lymphatic mapping

被引:25
|
作者
Posther, KE
Wilke, LG
Giuliano, AE
机构
[1] Duke Univ, Med Ctr, Amer Coll, Surg Oncol Grp,Dept Surg, Durham, NC 27710 USA
[2] John Wayne Canc Inst, Dept Surg Oncol, St Johns Hlth Ctr, Santa Monica, CA USA
关键词
D O I
10.1053/j.seminoncol.2004.03.019
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The current national sentinel lymph node (SLN) clinical trials for breast carcinoma address the prognostic and therapeutic utility of SLN dissection (SLND) in women with early-stage, clinically node-negative breast cancer. Following completion of these studies, overall survival, disease-free survival, morbidity, and quality of life of patients will be compared. Surgeon participation is crucial to the ongoing success of clinical trials in the field of breast cancer surgery. © 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:426 / 436
页数:11
相关论文
共 50 条